+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter trial with high-dose chemotherapy and autograft as primary treatment for advanced follicular lymphoma



Multicenter trial with high-dose chemotherapy and autograft as primary treatment for advanced follicular lymphoma



Blood 94(10 SUPPL 1 PART 1): 171a, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 035349965

Download citation: RISBibTeXText


Related references

Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. Journal of Clinical Oncology 26(19): 3166-3175, 2008

German multicenter trial of high dose chemotherapy with stem cell support as primary treatment of advanced ovarian cancer. Bone Marrow Transplantation 22(SUPPL 3): S95-S96, 1998

Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) has better EFS and PFS than R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: A multicenter randomized GITMO/IIL trial. Journal of Clinical Oncology 24(18_suppl): 7525-7525, 2016

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105(10): 3817-3823, 2005

Multicenter Prospective Randomized GITMO Trial Comparing High Dose Sequential Chemotherapy with Autografting and CHOP Both Supplemented with Rituximab as Frontline Therapy for High-Risk Follicular Lymphoma Patients An Interim Analysis. Blood 100(11): Abstract No 4769, November 16, 2002

Long-term follow-up of low-grade lymphoma patients receiving high-dose chemotherapy with autograft as primary treatment. Blood 94(10 SUPPL 1 PART 2): 406b, Nov 15, 1999

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma. Blood 98(11 Part 2): 394b, November 16, 2001

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. British Journal of Haematology 116(1): 229-235, January, 2002

Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leukemia & Lymphoma 55(1): 51-55, 2014

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113(5): 995-1001, 2008

The GITMO experience with high-dose chemotherapy and autografting in advanced follicle centre lymphoma A multicenter trial showing good feasibility and frequent achievement of clinical and molecular remissions. Blood 98(11 Part 1): 678a-679a, November 16, 2001

Treatment of Follicular and Mantle Cell Lymphoma with Rituximab after High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation A Multicenter Phase II Study. Blood 100(11): Abstract No 2532, November 16, 2002

A multicenter randomized trial by Italian Lymphoma Intergroup comparing high dose chemotherapy with autologous stem cell transplantation vs intensified chemotherapy MegaCEOP in high risk diffuse large cell lymphoma No difference in outcome and toxicity. Blood 98(11 Part 1): 725a-726a, November 16, 2001

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 94(9): 1250-1258, 2009